New Triple-Drug attack shows promise for tough lung cancer
NCT ID NCT04958811
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 28 times
Summary
This study tests whether adding tiragolumab to standard immunotherapy (atezolizumab) and anti-angiogenesis therapy (bevacizumab) can shrink tumors in people with advanced non-squamous non-small-cell lung cancer that has worsened after prior treatment. About 29 adults with specific genetic profiles are enrolled. The main goal is to see how many patients respond, while also monitoring side effects and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.